


Synthesis of Enantiomerically Pure Desmethyl C,D-Ring Derivative of Paclitaxel (Taxol™) via Asymmetric Diels-Alder Reaction of 2-Siloxyfuran

Chin-Kang Sha,* Shin-Jen Lee and Wei-Hong Tseng

Department of Chemistry, National Tsing Hua University, Hsinchu 300, Taiwan, R. O. C.


Abstract: Cycloadduct **3** of the asymmetric Diels-Alder reaction of 2-siloxyfuran **2** and dimethyl acetylenedicarboxylate was converted into the enantiomerically pure desmethyl C,D-ring derivative **13** of Paclitaxel. © 1997 Elsevier Science Ltd.

Paclitaxel (Taxol™) **1**, as a potent anti-cancer agent has been approved for the treatment of ovarian and breast cancers.¹ Evaluation for the treatment of other carcinomas is now being conducted in many institutions.² Not only due to its high therapeutic promise but also owing to its intricate molecular structure, paclitaxel has become one of the most attractive target for total synthesis in recent years.




1

To date, three total syntheses of paclitaxel have been reported.³ Several excellent reviews on the approaches toward the total synthesis of paclitaxel and its analogues have appeared.⁴ In a typical convergent approach, A-ring and C,D-ring portions of paclitaxel were synthesized separately. These two portions were then coupled to construct the eight membered B-ring of the paclitaxel skeleton. Due to its stereochemistry and the presence of an oxetane subunit, the synthesis of the C,D-ring^{4c,5} itself is a challenging problem. In our laboratories, we recently have developed a protecting-group-enhanced asymmetric Diels-Alder reaction of 2-siloxyfurans with high diastereofacial selectivity.⁶ Herein we report the application of this asymmetric Diels-Alder reaction toward the synthesis of enantiomerically pure desmethyl C,D-ring derivative **13**.



Asymmetric Diels-Alder reaction of 2-siloxyfuran **2**⁷ with dimethyl acetylenedicarboxylate was carried out in 5 M lithium perchlorate ether solution⁸ at room temperature to give cycloadducts **3** and **4** in excellent diastereofacial selectivity⁹ (1:12, 83%). Cycloadducts **3** and **4** were separated readily by silica-gel flash column chromatography. Compound **4** was then treated with magnesium in methanol to give diesters **5** (*bis-endo-cis* isomer as the major product along with some minor *trans* isomer, 4:1). The mixture of diesters was treated with iodine and silver trifluoroacetate to afford iodo lactone **6** (82% from **4**). Reduction of iodo lactone **6** by lithium aluminum hydride yielded **7** (60%). Protection of the primary alcohols in **7** as the pivalates and the secondary alcohol as the ethoxyethyl ether gave compound **8** (96%). Removal of the *t*-butyldimethylsilyl group and cleavage of the oxygen bridge of **8** was effected by zinc bromide in dichloromethane at 0 °C to give ketone **9**. L-Selectride reduction of **9** yielded **10** (84% from **8**) with the desired stereochemistry. Double methylation of diol **10** by potassium hydride and iodomethane followed by deprotection with HCl in methanol gave triol **11** (86%). Oxidative cleavage of the vicinal diol in **11** by lead tetraacetate and subsequent reductive workup using sodium borohydride yielded compound **12** (90%). Methanesulfonation of **12** followed by the treatment with sodium hydride in refluxing diethyl ether produced the desmethyl C,D-ring derivative **13**¹⁰ (84%). The stereochemistry of **13** was confirmed by ¹H NMR NOE experiment. Irradiation at H_c in **13** induces NOE at H_a (2.8 %), H_b (5 %) and α-OCH₃ (12 %) as shown below. This clearly indicated that the stereochemistry of H_a, H_b, H_c and α-OCH₃ are in *cis* relationship.



In summary, we have accomplished an efficient synthesis of enantiomerically pure desmethyl C,D-ring derivative **13** of paclitaxel via an asymmetric Diels-Alder reaction of 2-siloxyfuran **2**. We are currently investigating the stereoselective construction of paclitaxel framework by this approach in our laboratory.

Acknowledgments: We gratefully acknowledge a grant (NSC85-2113-M-007-016) from the National Science Council of the Republic of China.

References and Notes:

- (a) Straubinger, R. M. in *Taxol[®] Science and Applications*, Suffness, M. Ed.; CRC Press: New York, 1995; Chapter 9, pp. 237. (b) Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Forman, A. D.; Newton, L. K.; Raber, M. N.; Buzdar, A. U.; Frye, D. H.; Hortobagyi, G. N. *J. Natl. Cancer Inst.* **1991**, *83*, 1797. (c) Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. *J. Natl. Cancer Inst.* **1990**, *82*, 1247.
- (a) Arbuck, S. G.; Blaylock, B. A. in *Taxol[®] Science and Applications*, Suffness, M. Ed.; CRC Press: New York, 1995; Chapter 14, pp. 379. (b) Einzig, A. I.; Hochster, H.; Wiernik, P. H.; Trump, D. L.;

- Dutcher, J. P.; Garowski, E.; Sasloff, J.; Smith, T. J. *Invest. New Drugs* **1991**, *9*, 59. (c) Legha, S. S.; Ring, S.; Papadopoulos, N.; Raber, M. Benjamin, R. *S.Cancer* **1990**, *65*, 2478. (d) Chang, A. Y.; Kim, K.; Glick, J.; Anderson, T.; Karp D.; Johnson, D. *J. Natl. Cancer Inst.* **1993**, *85*, 388.
3. (a) Holton, R. A.; Somoza, C.; Kim, H. H.; Liang, F.; Biediger, R.; Boatman, P.; Shindo, M.; Smith, C.; Kim, S.; Nadizadeh, H.; Suzuki, Y.; Tao, C.; Vu, P.; Tang, S.; Zhang, P.; Murthi, K.; Gentil, L.; Liu, J. *J. Am. Chem. Soc.* **1994**, *116*, 1597, 1599. (b) Nicolaou, K. C.; Yang, Z.; Sorensen, E. J. *Nature* **1994**, *367*, 630. (c) Masters, J. J.; Link, J. T.; Snyder, L. B.; Young, W. B.; Danishefsky, S. J. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 1723.
4. (a) Nicolaou, K. C. in *Classics in Total Synthesis*, Nicolaou, K. C.; Sorrenson, E. J. Eds.; VCH Weinheim: 1996; Chapter 34, pp.655. (b) Wender, P. A.; Natchus, M. G.; Shuker, A. J. In *Taxol® Science and Applications*, Suffness, M. Ed.; CRC Press: New York, 1995; Chapter 6, pp. 123. (c) Swindell, C. S. *Organic Preparations and Procedures International* **1991**, *23*, 465. (d) Nicolaou, K. C.; Dai, W.-M.; Guy, R. K. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 15. (e) Boa, A. N.; Jenkins, P. R.; Nawrence, N. J. *Contemporary Organic Synthesis* **1994**, *1*, 47.
5. For the recent references on the synthesis of C,D-ring of taxol see: (a) Berkowitz, W. F.; Amarasekara, A. S. *Tetrahedron Lett.* **1985**, *26*, 3663. (b) Berkowitz, W. F.; Amarasekara, A. S.; Perumattam, J. J. *J. Org. Chem.* **1987**, *52*, 1119. (c) Lin, J.; Nikaido, M. M.; Clark, G. *J. Org. Chem.* **1987**, *52*, 3745. (d) Nicolaou, K. C.; Hwang, C.-K.; Sorenson, E. J.; Clairborne, F. *J. Chem. Soc., Chem. Commun.* **1992**, 1117. (e) Magee, T. V.; Bornmann, W. G.; Issacs, I. C. A.; Danishefsky, S. J. *J. Org. Chem.* **1992**, *57*, 3274. (f) Nicolaou, K. C.; Liu, J. J.; Hwang, C.-K.; Dai, W.-M.; Guy, R. K. *J. Chem. Soc., Chem. Commun.* **1992**, 1118. (g) Wender, P. A.; Rawlins, D. B. *Tetrahedron* **1992**, *48*, 7033. (h) Isaacs, R. C.; Di Grandi, M. J.; Danishefsky, S. J. *J. Org. Chem.* **1993**, *58*, 3938. (i) Yadav, J. S.; Ravishankar, R.; Lakshman, S. *Tetrahedron Lett.* **1994**, *35*, 3621.
6. Sha, C.-K.; Shen, C.-Y.; Lee, R.-S.; Lee, S.-R. *Tetrahedron Lett.* **1995**, *36*, 1286.
7. (a) Vakemans, J. A. J. M.; Boerekamp, J.; Godefroi, E. F.; Chittenden, G. J. F. *Recl. Trav. Chim. Pays-Bas.* **1985**, *104*, 266. (b) Vakemans, J. A. J. M.; Franken, G. A. M.; Dapperens, C. W. M.; Godefroi, E. F.; Chittenden, G. J. F. *J. Org. Chem.* **1988**, *53*, 627.
8. Grieco, P. A.; Nunes, J. J.; Gaul, M. D. *J. Am. Chem. Soc.* **1990**, *112*, 4595.
9. For the effect of diarylhydroxymethyl group on asymmetric reactions, see: Braun, M. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 519.
10. Data of compound **13**: $[\alpha]^{23}_{\text{D}} = -15.1^{\circ}$ (c 0.5, CHCl_3). IR (neat) 2939, 1728, 1474, 1397, 1234, 1156, 1034 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ 4.79 (dd, $J = 2.0, 6.8$ Hz, 1 H), 4.53 (A of AB, d, $J = 7.0$ Hz, 1 H), 4.41 (B of AB, d, $J = 7.0$ Hz, 1 H), 4.37-4.26 (m, 4 H), 3.48 (m, 1 H), 3.30 (s, 3 H), 3.23 (s, 3 H), 2.33 (td, $J = 5.2, 9.2$ Hz, 1 H), 2.12 (ddd, $J = 2.0, 4.2, 16.0$ Hz, 1 H), 2.05 (tdd, $J = 7.6, 2.4, 9.2$ Hz, 1 H), 1.81 (m, 1 H). ^{13}C NMR (75 MHz, CDCl_3) δ 178.12 (C=O), 177.90 (C=O), 82.96 (CH), 76.46 (C), 74.54 (CH_2), 74.44 (CH), 63.27 (CH_2), 63.06 (CH_2), 56.60 (CH_3), 50.45 (CH_3), 38.84 (CH), 38.69 (C), 37.55 (CH), 31.56 (CH_2), 27.24 (CH_3). MS (FAB) m/z 401($\text{M}^+ + \text{H}$, 5), 299 (44), 165 (19), 135 (20), 85 (22), 57 (100). HRMS (FAB, $\text{M}^+ + \text{H}$) calcd for $\text{C}_{21}\text{H}_{37}\text{O}_7$ 401.2539, found 401.2549.

(Received in China 4 November 1996; revised 18 November 1996; accepted 9 January 1997)